Insmed Inc (INSM)
Insmed Inc. is a NASDAQ-listed biotechnology company focused on developing and commercializing therapies for people with serious and rare diseases in the United States, Europe, Japan, and other international markets. Its marketed product includes ARIKAYCE for refractory nontuberculous mycobacterial lung infections. The company also has several development programs in clinical testing, including brensocatib for bronchiectasis and other inflammatory conditions, treprostinil palmitil inhalation powder for pulmonary hypertension-related disorders, and gene therapy candidates such as INS1201 and INS1202. Additional programs include INS1148 and pre-clinical research efforts in gene therapy, protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Insmed was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INSM
|
$102.48
|
-14.6% Downside
|
Fair
|
$199.55
|
66.3% Upside
|
Bargain
|
Fair
|
0.0%
|
October 22, 2026
|
35.7x
|
23.8x
|
26.206 B
|
26.654 B
|
2.7%
|
99.3%
|
7.7
|
92.3%
|
